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Key points summary 
- Blood flow through intrapulmonary arteriovenous anastomoses (IPAVA) is 
increased by acute hypoxia during rest by unknown mechanisms. 
- Oral administration of acetazolamide blunts the pulmonary vascular pressure 
response to acute hypoxia, thus permitting the observation of IPAVA blood flow 
with minimal pulmonary pressure change. 
- Hypoxic pulmonary vasoconstriction (HPV) was attenuated in humans following 
acetazolamide administration and partially restored with bicarbonate infusion, 
indicating that the effects of acetazolamide on HPV may involve an interaction 
between arterial pH and PCO2.  
- We observed that IPAVA blood flow during hypoxia was similar before and 
following acetazolamide administration, even after acid-base status correction, 
indicating pulmonary pressure, pH, and PCO2 are unlikely regulators of IPAVA 
blood flow. 
Word count: 114 
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Abstract 
Blood flow through intrapulmonary arteriovenous anastomoses (IPAVA) is increased with 
exposure to acute hypoxia and has been associated with pulmonary artery systolic pressure 
(PASP).  We aimed to determine the direct relationship between blood flow through 
IPAVA and PASP in 10 participants with no detectable intracardiac shunt by comparing: 
(1) isocapnic hypoxia (control); (2) isocapnic hypoxia with oral administration of 
acetazolamide (AZ; 250 mg, three times-a-day for 48 h) to prevent increases in PASP, and 
(3) isocapnic hypoxia with AZ and 8.4% NaHCO3 infusion (AZ+HCO3
-) to control for AZ-
induced acidosis.  Isocapnic hypoxia (20 min) was maintained by end-tidal forcing, blood 
flow through IPAVA was determined by agitated saline contrast echocardiography and 
PASP was estimated by Doppler ultrasound.  Arterial blood samples were collected at rest 
before each isocapnic-hypoxia condition to determine pH, [HCO3
-], and PaCO2.  AZ 
decreased pH (-0.08 ± 0.01), [HCO3
-] (-7.1 ± 0.7 mmol/l), and PaCO2 (-4.5 ± 1.4 mmHg; 
p<0.01), while intravenous NaHCO3 restored arterial blood gas parameters to control 
levels.  Although PASP increased from baseline in all three hypoxic conditions (p<0.05), 
a main effect of condition expressed an 11 ± 2% reduction in PASP from control (p<0.001) 
following AZ administration while intravenous NaHCO3 partially restored the PASP 
response to isocapnic hypoxia. Blood flow through IPAVA increased during exposure to 
isocapnic hypoxia (p<0.01) and was unrelated to PASP, cardiac output and pulmonary 
vascular resistance for all conditions. In conclusion, isocapnic hypoxia induces blood flow 
through IPAVA independent of changes in PASP and the influence of AZ on the PASP 
response to isocapnic hypoxia is dependent upon the H+ concentration or PaCO2.  
Abbreviations list: AZ, acetazolamide; FEV1, forced expiratory volume in 1 second; 
FIO2, fraction of inspired oxygen; FVC, forced vital capacity; Hb, total haemoglobin; 
HPV, hypoxic pulmonary vasoconstriction; HR, heart rate; IPAVA, intrapulmonary 
arteriovenous anastomoses; MAP, mean arterial pressure; PASP, pulmonary artery 
systolic pressure; PETCO2, end-tidal partial pressure of carbon dioxide; PETO2, end-tidal 
partial pressure of oxygen; PFO, patent foramen ovale; PVR, pulmonary vascular 
resistance; Q̇c, cardiac output; RVOT, right ventricular outflow tract; SpO2, 
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oxyhaemoglobin saturation; SV, stroke volume; TRV, tricuspid regurgitant velocity; V̇E, 
minute ventilation; VTI, velocity-time integral
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Introduction  
The anatomical evidence of intrapulmonary arteriovenous anastomoses (IPAVA) is established 
in many mammals, including baboons, dogs, and humans (Tobin & Zariquiey, 1950; Tobin & 
Wilder, 1953; Tobin, 1966; Lovering et al., 2007; Stickland et al., 2007).  In cadaveric human 
studies, IPAVA vessel diameter has been shown to be up to 200 µm in adults (Tobin, 1966), 
potentially indicating a transpulmonary pathway for erythrocytes that bypasses the alveoli.  
Indeed, this has been demonstrated in isolated human lungs; transpulmonary passage of 
microspheres exists, even if the microspheres are too large (50 µm) to pass through the alveolar 
capillaries (7-10 µm) (Lovering et al., 2007).  Similarly, blood flow through IPAVA can be 
detected in humans by agitated saline contrast echocardiography (Elliott et al., 2011; Elliott et 
al., 2013) or 99mTc macroaggregated albumin (Lovering et al., 2009b; Bates et al., 2014).  
Despite the anatomical and biophysical evidence, the functional significance of IPAVA (if any) 
is unclear. 
Previous reports speculate that IPAVA act as a pressure release valve (Berk et al., 1977; 
Stickland et al., 2004), diverting blood flow away from the fragile microvessels of the lung and 
consequently reducing the risk of capillary stress failure and pulmonary oedema.  The proposed 
protective mechanism has been supported most recently by Norris et al. (2014) who described a 
relationship between high magnitudes of blood flow through IPAVA, as estimated by 
microbubble passage, and total pulmonary resistance. Subjects who demonstrated a high amount 
of microbubble passage (i.e. bubble score ≥ 2) had lower total pulmonary resistance compared to 
those with less microbubble passage (i.e. bubble score < 2).  On the other hand, while blood flow 
through IPAVA may serve to relieve capillary hydrostatic pressure it may also decrease gas 
exchange efficiency by allowing blood to bypass sites of pulmonary gas exchange.  Indeed, a 
correlation (r = 0.63 - 0.68) between the change in 99mTc macroaggregates or the occurrence of 
saline contrast passage and the alveolar-arterial oxygen gradient has been observed during 
normoxic and hypoxic exercise (Stickland et al., 2004; Bates et al., 2014). Although its 
physiological contribution as an anatomical shunt remains a matter of debate (Hopkins et al., 
2009; Lovering et al., 2009a), recent work by Bryan et al. (2012) and Elliott et al. (2014) 
indicate that blood flow through IPAVA does contribute to pulmonary gas exchange efficiency.  
Given these potential protective (i.e. reduced capillary stress) and detrimental (i.e. decreased gas 
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exchange efficiency) effects of blood flow through IPAVA, it is important to understand the 
stimuli or mechanisms responsible for regulating blood flow through IPAVA.   
 Blood flow through IPAVA is present in approximately 30% of healthy individuals 
without a patent foramen ovale (PFO) under normal resting physiological conditions (Elliott et 
al., 2013).  Both acute hypoxia and cycle exercise in normoxia have been utilised to recruit 
IPAVA pathways in nearly all participants (Eldridge et al., 2004; Stickland et al., 2004; 
Lovering et al., 2006; Lovering et al., 2008a; Laurie et al., 2010; Kennedy et al., 2012; Bates et 
al., 2014; Foster et al., 2014).  Using participants without a PFO or other cardiac shunt, >90% of 
participants demonstrated intrapulmonary saline contrast passage during submaximal and 
maximal exertion (Eldridge et al., 2004; Stickland et al., 2004; Lovering et al., 2008a).  An 
increasing magnitude of bubble score with decreasing fraction of inspired oxygen (FIO2) 
observed by Laurie et al. (2010) indicates that the mechanism of IPAVA recruitment likely owes 
to a common physiological mechanism found during both exercise and hypoxia.  
 The principal stimulus ultimately responsible for regulating IPAVA recruitment is 
unknown; however, the literature suggests that pulmonary blood flow, pressure, or alveolar 
hypoxia are likely mediators (Laurie et al., 2010; Laurie et al., 2012; Elliott et al., 2014).  In 
humans, progressive hypoxia appears to promote a graded increase in the magnitude of 
microbubble passage despite a small increase in pulmonary artery systolic pressure (PASP) 
(Laurie et al., 2010), indicating that alveolar hypoxia may be more important than pulmonary 
vascular pressure.  The results from studies using cycle exercise to increase blood flow through 
IPAVA illustrate that an increase in microvascular pressure secondary to the increase in flow 
recruits IPAVA and reduces pulmonary vascular resistance (PVR) (Stickland et al., 2004).  
However, in a subsequent study, Stickland et al. (2006) found that microbubble passage through 
IPAVA was inconsistent with increasing mean pulmonary artery pressure, finding greater 
consistency with increased cardiac output (Q̇c), implicating pulmonary blood flow as the primary 
mediator of blood passage through IPAVA.  Recent work by Elliott et al. (2014) suggest that 
increased Q̇c, independent of increased PASP, increases blood flow through IPAVA in subjects 
breathing room air and mild hyperoxia (40% O2).  The conflicting results between studies 
prompted us to determine the importance of pulmonary vascular pressure on hypoxia induced 
blood flow through IPAVA.   
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Acetazolamide (AZ) is a carbonic anhydrase inhibitor that induces an acidosis, a mild 
diuresis, can inhibit hypoxic pulmonary vasoconstriction (HPV) and is commonly used to treat 
and prevent acute mountain sickness (Swenson, 2006; Hohne et al., 2007; Swenson, 2014).  
Previously AZ, has been demonstrated to reduce the pulmonary pressure response to isocapnic 
hypoxia in humans by approximately 57% (Teppema et al., 2007). Therefore, administration of 
AZ permits the observation of blood flow through IPAVA during hypoxia with minimal changes 
in PASP. 
 Based on the above brief summary, the purpose of this investigation was two-fold:  first, 
to determine if the stimulus for IPAVA recruitment in response to isocapnic hypoxia is hypoxia, 
elevated pulmonary arterial pressure, or arterial pH/PCO2; and second, to determine if AZ 
inhibits HPV through metabolic acidosis.  We hypothesized: (1) that exposure to isocapnic 
hypoxia would lead to an increase in PASP and blood flow through IPAVA; (2) that oral 
administration of AZ would blunt the PASP response to hypoxia and abolish blood flow through 
IPAVA independent of arterial pH.   
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Methods 
Ethical approval.  All experimental procedures and protocols were approved by the Clinical 
Research Ethics Board at the University of British Columbia, and conformed to the latest 
revision of the Declaration of Helsinki.  All participants provided written informed consent prior 
to participation in this study. 
Participants.  Healthy adult human participants free from cardiopulmonary disease participated 
in this study.  Participants were excluded if they were obese (body mass index > 30 kg m-2), had 
a history of smoking (within the past year), were hypertensive (systolic blood pressure > 140 
mmHg; diastolic blood pressure > 90mmHg) or had poor pulmonary function as determined by 
spirometry (i.e., FEV1/FVC < 0.75).  Since the purpose of this study was to investigate the 
mechanisms controlling blood flow through IPAVA, participants were excluded if they had a 
PFO at rest or with a provocative manoeuvre (see Experimental Protocol).  Finally, participants 
were excluded if they had pulmonary hypertension (PASP > 35mmHg) determined by 
echocardiography (see Pulmonary Haemodynamics).  These exclusion criteria ensured that the 
participants included in this study were healthy and free from cardiopulmonary disease.  In total, 
27 participants were screened, and 11 qualified for the study.  An incomplete Doppler envelope 
of the tricuspid regurgitant jet necessitated the exclusion of an additional participant.  The results 
presented, unless otherwise specified, are based on 10 participants (1 female) between the ages 
of 22 and 37 years.  
Experimental Protocol.  Participants attended the laboratory on three separate days to complete 
this study.  Visits two and three were separated by a minimum of four days.  Inclusion/exclusion 
criteria were assessed on the first visit and participants were familiarised with the breathing 
apparatus and echocardiography measurements.   Height and weight were measured, spirometry 
was conducted in accordance with the standards outlined by the American Thoracic Society and 
the European Respiratory Society (Miller et al., 2005), and participants were instrumented with 
an intravenous catheter at the antecubital fossa.  Following 10 minutes of supine rest, three 
consecutive blood pressure measurements were obtained from the right upper arm by using a 
manual sphygmomanometer and stethoscope for auscultation of Korotkoff sounds.  While in the 
supine position, collapse of the inferior vena cava during a rapid inspiration was imaged by 
ultrasound to estimate right atrial pressure (Yildirimturk et al., 2011).  The participant was then 
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positioned laterally on their left side and echocardiographic images were recorded to determine 
stroke volume (SV) and PASP (see Pulmonary Haemodynamics).  Beat-to-beat blood pressure 
was measured by finger pulse photoplethysmography (Finometer PRO, Finapress Medical 
Systems, Amsterdam, Netherlands) and normalised to manual cuff measurements of the brachial 
artery.  Mean arterial pressure (MAP) was calculated from the beat-to-beat recordings.  Heart 
rate (HR) was measured by standard lead-II electrocardiogram.  Next, an apical 4-chamber view 
of the heart was acquired and the presence or absence of intracardiac shunt or blood flow through 
IPAVA was determined by the technique of agitated saline contrast echocardiography (Kennedy 
et al., 2012; Elliott et al., 2013; Foster et al., 2014).  Agitated saline contrast echocardiography 
was repeated during the release of a Valsalva manoeuver as a provocative stimulus to ensure the 
patency of the foramen ovale was identified appropriately.   
Participants identified as PFO negative (n = 11) returned within a week and breathed 20 
minutes of isocapnic hypoxia (Control; PETO2 = 47 mmHg) to determine pulmonary 
haemodynamics and blood flow through IPAVA during an acute hypoxic exposure in a supine 
position.  This protocol was selected based on Laurie et al. (2010) who demonstrated an 
oxyhaemoglobin saturation (SpO2) of 79.8 ± 4.7% with FIO2 of 0.12 and was sufficient to recruit 
IPAVA in all participants under resting hypoxic conditions.  Pulmonary haemodynamics and 
blood flow through IPAVA were measured by echocardiogram during 5 minutes of rest and the 
last 5 minutes of hypoxia.  Participants were then prescribed an oral dose of AZ (250 mg) every 
8 hours for 2 days prior to their final laboratory visit.  The final dose of AZ was taken one hour 
before experimentation.  This pharmacological treatment is known to nearly abolish the 
pulmonary pressor response to hypoxia in humans and animals (Hohne et al., 2007; Teppema et 
al., 2007).  The isocapnic hypoxia protocol was then repeated twice (separated by at least 30 
minutes) without intravenous NaHCO3 (AZ) and with intravenous NaHCO3
- (AZ+HCO3
-).  To 
control for the metabolic acidosis caused by AZ, an 8.4% intravenous NaHCO3
- solution 
(Hospira, Montreal, Quebec, Canada) was delivered over a 15-minute period to restore arterial 
pH to resting levels.  Arterial blood samples were collected from the radial artery before each 
exposure to isocapnic hypoxia and, in a subgroup of participants (n = 7), following the 
AZ+HCO3
- protocol to ensure that pH and [HCO3
-] were maintained for the duration of the 
experimental protocol.  The deficit in [HCO3
-] was calculated from resting arterial [HCO3
-] taken 
with and without AZ and using body mass to calculate the required dosage of NaHCO3 (Kollef & 
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Isakow, 2012).  Arterial blood gas samples were obtained after bicarbonate infusion to ensure 
sufficient normalisation.  In the event that [HCO3
-] was not completely restored to resting levels 
additional NaHCO3
- was infused and bicarbonate levels re-assessed prior to experimentation.  
The order of experiments was not randomized because of the lasting effects of AZ and NaHCO3. 
Pulmonary Haemodynamics.  All echocardiography measurements were performed using the 
same commercially available ultrasound system (Vivid Q, 3.5 MHz transducer, GE Healthcare) 
by the same experienced sonographer (M.S.).  First, the diameter of the left ventricular outflow 
tract at the level of the aortic annulus was determined from the parasternal long axis view.  
Measurements were taken at the end of systole and the average of three cardiac cycles taken as 
the diameter of the aorta.  Then, the velocity time integral (VTI) of the left ventricular outflow 
tract was obtained from an apical five-chamber view by placing a pulsed wave Doppler sample 
volume just within the aortic valve.  SV was calculated as the product of the VTI and aortic area, 
and Q̇c was obtained by multiplication with HR.  These methods have been previously described 
and validated against thermodilution and direct Fick (Christie et al., 1987).  Tricuspid 
regurgitation peak velocity was identified using colour flow Doppler and measured by 
continuous-wave Doppler ultrasound from the apical four-chamber view.  The pulmonary artery 
pressure gradient could then be estimated from the simplified Bernoulli equation and PASP 
could be estimated by addition of right atrial pressure (Vazquez de Prada et al., 1987).  The 
inferior vena cava diameter was measured from subcostal longitudinal images approximately 2 
cm distal to the right atrial junction.  The collapsibility index was calculated as the percentage of 
difference between maximal and minimal size of the inferior vena cava.  Right atrial pressure 
was predicted using the collapsibility index as recommended by the American Society of 
Echocardiography (Rudski et al., 2010).  This method has been validated against right atrial 
pressure obtained directly by right heart catheterisation (Yildirimturk et al., 2011).  All 
pulmonary haemodynamic measurements were made on three cardiac cycles and averaged to 
provide a single value.  Pulmonary vascular resistance was obtained from the ratio of the peak 
tricuspid valve regurgitation (TRV) to the right ventricular outflow tract time-velocity integral 
(TVI RVOT).  This was subsequently converted to Woods units (wu) (PVR = TRV(TVI 
RVOT × 10 + 0.16)-1).  This noninvasive estimate of PVR correlates well with invasive 
measurements (Abbas et al., 2003; Roule et al., 2010). 
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Agitated Saline Contrast Echocardiography.  The presence of intracardiac shunt (i.e., PFO) was 
determined under resting conditions and during a provocative stimulus (i.e., release from 
Valsalva) using the technique of agitated saline contrast echocardiography (Marriott et al., 
2013).  Two 5-ml syringes were connected by three-way stopcocks and attached to the 22-gauge 
cannula placed in the antecubital vein.  One syringe contained 4 ml of sterile saline and the other 
0.5 ml of air.  The two syringes were flushed back and forth forcefully to agitate the mixture 
prior to rapid injection.  The agitated contrast was then visualised entering the right ventricle 
from an apical 4-chamber view of the heart.  If no bubbles appeared in the left ventricle, a 
provocative manoeuver was used to further assess the patency of the foramen ovale.  In this case, 
participants were instructed to Valsalva at the end of a normal expiration.  Agitated contrast was 
subsequently injected and once visualised in the right atrium, the participants were asked to relax 
and breathe normally.  A PFO was identified if contrast appeared in the left ventricle in ≤5 
cardiac cycles after the contrast cloud filled the right atrium.  After all contrast injections, a 
minimum of 20 cardiac cycles were recorded.  All participants with a PFO were excluded from 
this study. Blood flow through an IPAVA was defined when contrast appeared in the left 
ventricle > 5 cardiac cycles after the contrast appeared in the right atrium.  This technique has 
been used to investigate blood flow through IPAVA in participants during rest and exercise at 
sea level breathing room air and during acute normobaric hypoxia (Stickland et al., 2004; Imray 
et al., 2008; Kennedy et al., 2012; Laurie et al., 2012; Elliott et al., 2013).  A scoring system has 
been established to determine the severity of blood flow through IPAVA based on the greatest 
density and spatial distribution of microbubbles in the left ventricle of a single cardiac cycle 
during the subsequent 20 cardiac cycles (Lovering et al., 2008b).  This 0-5 scoring system 
assigns a ‘0’ for no microbubbles; ‘1’ for 1-3 microbubbles; ‘2’ for 4-12 microbubbles; ‘3’ for 
greater than 12 microbubbles bolus; ‘4’ for greater than 12 microbubbles heterogeneously 
distributed; and a ‘5’ for greater than 12 microbubbles homogeneously distributed.  This scaling 
system is reproducible between independent blinded observers (Laurie et al., 2010).  All agitated 
saline contrast echocardiograms were reviewed and scored by the same experienced sonographer 
(M.S.) 
Isocapnic Hypoxia.  Respiratory parameters were acquired at 200 Hz using an analogue-to-
digital converter (PL3504, ADInstruments, Colorado Springs, USA) interfaced with a personal 
computer and analysed using commercially available software (LabChart, ADInstruments).  
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During the isocapnic hypoxia protocol participants breathed through a mouthpiece and two-way 
non-rebreathing valve with a nose clip applied to obstruct the nasal passage.  Respired gas 
pressures were sampled at the mouth and analysed for PO2 and PCO2 (ML206, ADInstruments).  
Respiratory flow was measured at the mouth using a pneumotachograph (HR 800L, Hans 
Rudolph, Shawnee, USA).  PETO2, PETCO2, inspiratory and expiratory tidal volumes were 
determined for each breath online using custom designed software (LabView V13.0, National 
Instruments, Austin, USA).  Oxyhaemoglobin saturation was measured continuously by pulse 
oximetry (ML320/F, ADInstruments). End-tidal oxygen was clamped at 47 mmHg and PETCO2 
was maintained at resting levels by using a portable end-tidal forcing system (AirForce, 
G.E.Foster, Kelowna, Canada) (Bain et al., 2013; Querido et al., 2013; Foster et al., 2014).   
Arterial Blood Gas Sampling.  Arterial blood gas samples were collected from the radial artery 
using a 23-gauge self-filling pre-heparanised syringe (safePICO syringes, Radiometer, 
Copenhagen, Denmark).  Approximately 3 ml of blood was withdrawn, air bubbles were 
immediately evacuated from the syringe and blood gas analysis was performed within 30 s of 
sampling with a calibrated blood gas analyser (ABL90 FLEX, Radiometer, Copenhagen, 
Denmark).  Arterial blood was analysed for pH, PaO2, PaCO2, haemoglobin ([Hb]) 
concentration, and [HCO3
-] was calculated from pH and PaCO2.  All samples were assumed to 
be collected at a resting body temperature of 37 degrees Celsius.  All samples were withdrawn 
after the participant had been resting supine for 10 minutes and immediately prior to exposure to 
isocapnic hypoxia.  In a subgroup of participants (n = 7), an additional sample was drawn after 
the AZ+HCO3
- experimental condition to confirm [HCO3
-] and pH were normalised. 
Statistical Analysis.  Statistical comparisons and calculations were made using statistical 
software (Statistica v.7.0, Statsoft Inc., Tulsa, OK, USA).  Participant resting characteristics were 
compared between the three conditions by one-way repeated measures analysis of variance 
(ANOVA).  Cardiopulmonary parameters were compared using a three-by-two (pharmacological 
intervention by normoxia/hypoxia) repeated measures ANOVA.  Blood sample parameters were 
compared using a one-way repeated measures ANOVA.  When significant F-ratios were 
detected, Tukey’s HSD was applied to determine where the differences lay.  Since we were most 
concerned about the differences between PASP during isocapnic hypoxia we compared these by 
one-way ANOVA.  Bubble scores were compared between groups by Friedman ANOVA, with 
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Dunn’s post-test if appropriate.  All data are presented as mean ± standard error (SE; unless 
otherwise noted) and statistical significance was set at p<0.05 for all comparisons. Where 
echocardiographic measurements were unsuccessful, a three-by-two factorial ANOVA was 
conservatively performed to enable comparison on groups of unequal subjects.  
Echocardiographic measurements were unsuccessful for two participants for SV, Q̇c and PVR 
during normoxic AZ; one participant for SV and Q̇c during hypoxic AZ; one participant for SV 
and Q̇c and two participants for PVR during normoxic AZ+HCO3-. 
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Results 
Participant characteristics 
Ten healthy adults met our inclusion criteria, participated in this study (age = 30 ± 2 years, 
height = 178 ± 3 cm, weight = 83 ± 4 kg) and had pulmonary function within normal limits 
(FEV1/FVC = 81 ± 2 % [104 ± 2 % predicted]).  In adherence to the inclusion criteria, none of 
the participants demonstrated microbubble passage through a PFO during rest or following 
release of a Valsalva manoeuver in normoxic conditions. 
Haematological measurements 
Haematological measurements obtained at rest before each condition and following AZ+HCO3
- 
are reported in Table 1.  A significant main effect of the pharmacological intervention was 
detected for PaCO2, pH and [HCO3
-].  Post hoc analysis revealed a significant reduction in 
arterial pH and [HCO3
-] following AZ administration (p<0.001) compared to control and 
AZ+HCO3
-.  PaCO2 at rest was significantly reduced during AZ compared to control (p<0.01).  
In the subset of participants (n = 7) with blood samples taken following the AZ+HCO3
- 
condition, arterial pH was reduced at this time point compared to AZ+HCO3
- (p<0.05), but was 
still greater than AZ (p<0.01) and similar to control (p = 0.06).  In addition, [HCO3
-] was lower 
than control and AZ+HCO3
- (p<0.01) but remained greater than AZ (p<0.01). 
Cardiopulmonary parameters during normoxia and hypoxia 
Figure 1 displays the group mean PETO2, PETCO2, and V̇E in 15-second intervals during 2 
minutes of baseline and throughout isocapnic hypoxia for all three conditions. Table 2 displays 
select cardiopulmonary parameters during normoxia and hypoxia for each condition.  PETCO2 
was significantly decreased during AZ and AZ+HCO3
- compared to control (p<0.001). The 
expected responses to hypoxia were similar in each condition for V˙  E, MAP and HR (Table 2).  
Effect of AZ and NaHCO3 on the PASP, Q̇c, and PVR response to hypoxia 
Figure 2 shows the individual and mean changes in PASP from normoxia to isocapnic hypoxia 
during each condition.  All participants displayed an increase in PASP following hypoxic 
exposure, with the exception of a single individual during control, in whom PASP fell from 27.2 
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mmHg to 26.0 mmHg and another following AZ, who displayed a reduction in PASP in hypoxia, 
from 22.4 mmHg to 20.5 mmHg. Excluding the two instances of PASP reduction upon hypoxic 
exposure, PASP increased from 20.5 ± 0.5 mmHg to 26.1 ± 1.1 mmHg in control, 19.0 ± 0.7 
mmHg to 21.4 ± 0.6 mmHg following AZ and 19.4 ± 0.6 mmHg to 23.7 ± 0.8 mmHg after 
NaHCO3 infusion.  A significant main effect of oxygen level was observed (i.e., normoxia vs 
hypoxia; p<0.001) such that PASP increased by 20 ± 2 % (p<0.001) during hypoxia.  A main 
effect of pharmacological intervention (i.e., control/AZ/AZ+HCO3
-; p<0.01) identified an 11 ± 2 
% decrease in PASP from control to AZ, while AZ+HCO3
- was similar to control (p = 0.09).  No 
interaction effect on PASP was detected (p = 0.22).  Cardiac output showed no effect of 
condition but increased by 0.9 ± 0.2 l min-1 with hypoxia (p<0.01).  Pulmonary vascular 
resistance rose by 0.1 ± 0.03 wu in hypoxia (p<0.05).  A main effect of condition on PVR was 
found (p<0.001), showing an elevation during AZ+HCO3
- of 15 ± 4 % (p<0.01) compared to 
control and by 14 ± 3 % (p<0.01) compared to AZ (Table 2). 
Blood flow through IPAVA 
During normoxia, one participant demonstrated microbubble passage in the control condition and 
another during AZ (bubble score = 1).  No participants displayed microbubble passage during 
normoxia in the AZ+HCO3
-.  Figure 4 displays the distribution of bubble scores for all 
conditions during hypoxia.  Only one participant did not demonstrate any microbubble passage 
during hypoxia control, the remaining 9 participants had a bubble score of 1 (n = 4) or 2 (n = 5).  
During AZ and AZ+HCO3
-, bubble scores were similar to control and included bubble scores of 
1 (n = 4), 2 (n = 4) and 3 (n = 2).  The two participants who scored a bubble score of 3 were the 
same in AZ and AZ+HCO3
-.  A significant increase in bubble score from normoxia to hypoxia 
(p<0.001) was found, but no effect of condition (p = 0.22).  Responses to the conditions during 
isocapnic hypoxia varied between participants.  Specifically, four participants displayed the same 
bubble score during all three interventions, AZ increased bubble score in four participants 
including one participant that increased from a score of 1 to 3, and sodium bicarbonate infusion 
decreased microbubble passage in a single participant while one participant demonstrated a 
lower bubble score during AZ that was reversed following AZ+HCO3
-.  Nevertheless, aside from 
one participant, all individual changes between conditions were only by a bubble score of one.    
Relationship between changes in PASP, Q̇c, PVR and blood flow through IPAVA 
 Page 17 of 40 
Figure 4 displays the relationship between PASP, Q̇c and PVR with bubble scores across the 
three conditions.  Multiple linear regressions did not reveal any significant correlations with R2 
values of 0.008, 0.12 and 0.003 for PASP, Q̇c and PVR, respectively.  In addition, we conducted 
linear regression analysis to determine if the subjects with the largest change in PASP with 
isocapnic hypoxia had the largest blunting by AZ.  We found a weak, non-significant correlation 
(R2 = 0.16, p = 0.19) between these parameters suggesting that the subjects with the largest 
PASP response had the smallest PASP response with AZ. 
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Discussion 
Main Findings 
The purpose of this investigation was to determine if the stimulus for IPAVA recruitment in 
response to isocapnic hypoxia is alveolar hypoxia, elevated pulmonary arterial pressure, or 
arterial pH/PCO2; and, to determine if AZ inhibits HPV through metabolic acidosis.  Acute 
isocapnic hypoxia induces blood flow through IPAVA.  By directly manipulating the pulmonary 
pressure response to isocapnic hypoxia with AZ we extend the findings of previous reports and 
illustrate that the magnitude of blood flow through IPAVA in response to isocapnic hypoxia is 
unrelated to changes in PASP, Q̇c, or PVR.  We suggest that blood flow through IPAVA occurs 
independent of changes in pulmonary artery pressure and instead may be regulated by alveolar 
hypoxia.  Similar to other reports we found that AZ blunts the PASP response to isocapnic 
hypoxia (Teppema et al., 2007).  However, we extend these findings by illustrating that the 
correction of arterial pH and [HCO3
-] induced by AZ by intravenous NaHCO3 infusion partially 
restored the PASP response to isocapnic hypoxia.  These data indicate that oral AZ may reduce 
the PASP response to hypoxia by reducing arterial/alveolar PCO2, since the correction of arterial 
pH and consequently PaCO2 partially normalised the PASP response to hypoxia. 
Hypoxia induces blood flow through IPAVA 
With the exception of one participant during control, exposure to 20 minutes of isocapnic 
hypoxia induced blood flow through IPAVA.  A unique finding was the absence of bubble scores 
of larger magnitude (i.e., >3).  Employing a similar duration (i.e., 30 minutes) and intensity of 
hypoxia (i.e., alveolar PO2 = 47 ± 1 mmHg) as our investigation, Laurie et al. (2010) found that 
50% of their participants achieved bubble scores greater than or equal to three, whereas only two 
participants from our study achieved a similar magnitude bubble score.  Achieving even greater 
magnitudes of blood flow through IPAVA, Norris et al. (2014) observed bubble passage in all 16 
young, healthy participants at FIO2 = 0.12 with 12 of these achieving scores ≥4.  Unlike the 
aforementioned studies, we maintained isocapnia throughout the hypoxic exposure to isolate the 
effects of hypoxia.  Carbon dioxide is an important modulator of HPV, with hypocapnia and 
subsequent alkalosis blunting HPV (Balanos et al., 2003; Ketabchi et al., 2009).  Alternatively, 
hypercapnia without accompanying pH changes may augment HPV (Brimioulle et al., 1990).  
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Based upon this assessment, poikilocapnic hypoxia may be an important modulator of blood 
flow through IPAVA.  Figure 5 displays the relationship between cardiac output and bubble 
score for our participants exposed to isocapnic hypoxia and the same relationship for participants 
exposed to poikilocapnic hypoxia from the study of Laurie et al. (2010).  Despite a similar range 
in cardiac output there was no relationship between these two variables in response to isocapnic 
hypoxia.  In summary, IPAVA appear to be recruited by hypoxia, while the use of isocapnic 
versus poikilocapnic hypoxia may have influenced the magnitude of blood passage through 
IPAVA.  Studies of similar levels of hypoxia may display greater bubble scores due to the 
influences of poikilocapnia.  Future research is needed to directly compare the magnitude of 
blood flow through IPAVA in response to isocapnic and poikilocapnic hypoxia in the same 
group of subjects. 
Haemodynamic influence on blood flow through IPAVA 
We successfully isolated acute isocapnic hypoxia from the consequent HPV by applying AZ to 
mitigate the rise in PASP during hypoxia.  While AZ decreased PASP from 23.6 ± 0.7 to 20.8 ± 
0.7 mmHg, it was not accompanied by a change in bubble score.  In fact, no haemodynamic 
measurements correlated with bubble score (see Figure 4).  Recent studies support an alveolar 
hypoxia-mediated recruitment of IPAVA.  Bates et al. (2014) observed greater 99mTc 
macroaggregate transit through IPAVA during resting hypoxia compared to exercise at the same 
level of hypoxia, indicating that increased pulmonary perfusion did not further increase blood 
flow through IPAVA in hypoxia.  Furthermore, Lozo et al. (2014) administered nitroglycerin, 
norepinephrine and aminophylline, to induce changes in Q̇c and PASP in 10 trained technical 
divers.  Nitroglycerin is a vasodilator that increases Q̇c at higher doses, norepinephrine increases 
systemic and pulmonary pressures and aminophylline is a pulmonary vasodilator.  None of these 
pharmacological agents induced blood flow through IPAVA despite increasing PASP from 21.6 
± 0.8 mmHg to 30.3 ± 1.6 mmHg following norepinephrine administration and significantly 
increasing Q̇c from 5.4 ± 0.4 l min-1 to 6.0 ± 0.4 l min-1 with aminophylline.  Further support for 
our finding of dissociation between haemodynamic parameters and bubble score comes from the 
absence of blood flow through IPAVA after acclimatization to high altitude.  In our recent study 
comparing sea-level and high-altitude IPAVA responses, we found that blood flow through 
IPAVA following 3 weeks acclimatisation to 5050 m was undetectable in 7 of our 8 sea-level 
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dwellers during the same protocol that induced blood flow through IPAVA at sea level, despite 
elevated PASP at high altitude (33 vs. 20 mmHg) (Foster et al., 2014).  Interestingly, Q̇c at high 
altitude was similar to normoxic conditions at sea level, indicating that blood flow through 
IPAVA is likely more closely related to changes in Q̇c than PASP.  This idea is consistent with 
the findings of Laurie et al. (2012) and Bryan et al. (2012) who showed that Q̇c was related to 
bubble score during dopamine, epinephrine, and dobutamine infusion and more recently by 
Elliott et al. (2014) who demonstrated and increase in IPAVA blood flow with increased Q̇c 
independent of increases in PASP.  In the current study, the lack of relationship between Q̇c and 
bubble score (see Figures 4 and 5) may be linked to isocapnia, as stated previously, but the fact 
that Q̇c was similar between all three conditions may have also contributed to the lack of 
differences in bubble score between conditions.  Based on this information, the primary mediator 
of IPAVA recruitment seems unlikely to be pressure-mediated and the contribution of pulmonary 
perfusion to blood flow through IPAVA cannot be entirely discounted.  
Acetazolamide and Hypoxic Pulmonary Vasoconstriction 
Acetazolamide led to a reduction in arterial pH, [HCO3
-], and PaCO2
 which can have a direct 
effect on pulmonary vessel tone.  Alkalosis and hypocapnia are known to blunt HPV, while 
acidosis and hypercapnia normally augment it (Ketabchi et al., 2009; Sylvester et al., 2012). Our 
results show that HPV is blunted following oral AZ administration and is partially restored with 
correction of [HCO3
-] (see Figure 2). The correction of the PASP response to hypoxia with 
[HCO3
-] correction may be due to the different levels of PETCO2 throughout each exposure as a 
result of the manipulation of arterial pH.  End-tidal carbon dioxide was clamped at baseline 
levels, thus, PETCO2 in the AZ condition was clamped at a lower level compared to control and 
AZ+HCO3
-.  A modest change in PETCO2 can influence the degree of the pulmonary pressure 
response in hypoxia (Croft et al., 2013).  Thus, the reduced increase in PASP from baseline 
induced by AZ during hypoxia (2.7 ± 0.7 mmHg with AZ compared to 4.9 ± 1.1 mmHg in 
control) could be attributed to the 4.2 ± 0.7 mmHg lower PETCO2 maintained throughout the 
isocapnic hypoxia protocol.  According to Croft et al. (2013) this ~5 mmHg difference in 
PETCO2 between conditions could account for approximately a 1.7 mmHg  difference in PASP 
when PETO2 was maintained at 50 mmHg.  Although the acid-base status was not controlled in 
their study, the acute HPV appears to be similar in hypercapnic acidosis and hypercapnia when 
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pH is maintained at resting levels (Ketabchi et al., 2009).  Therefore, the differences we 
observed in PASP response between control and AZ may be the result of differences in PaCO2, 
rather than the acid-base status.  However, while the majority of participants displayed modest 
HPV, AZ treatment only partially alleviated the slight rise in PASP.  Conversely, one participant 
had a substantial HPV response to hypoxia (PASP increased by 10.5 mmHg) and had complete 
abolishment of HPV following 48 hours of AZ administration. 
In our study, intravenous NaHCO3 normalised arterial pH, [HCO3
-] and PaCO2 and 
partially restored the PASP response to hypoxia.  While the mechanism whereby AZ attenuates 
HPV remains elusive, our data indicates that the reduction in PaCO2, secondary to carbonic 
anhydrase inhibition, alleviates the rise in PASP.  This is supported by a report demonstrating an 
inverse relationship between the hypoxic ventilatory response and HPV (Albert & Swenson, 
2014).  An augmented hypoxic ventilatory response would result in a greater reduction in PaCO2 
and a weakening of HPV.  Additionally, hypocapnia reduces acute HPV in humans (Balanos et 
al., 2003; Dorrington et al., 2010; Croft et al., 2013).  However, recent work in dogs indicates 
that the reduction in HPV with AZ is independent of any carbonic anhydrase inhibition.  Potent 
membrane-permeable and –impermeable carbonic anhydrase-inhibitors did not reduce the rise in 
pulmonary artery pressure upon exposure to hypoxia, though AZ did despite similar acid-base 
status, PaCO2 and V̇E across each intervention (Hohne et al., 2007).  This highlights that the 
mechanism of AZ on HPV reduction is independent of its known carbonic anhydrase-inhibiting 
effects in dogs.  The exact mechanism of AZ on HPV reduction in humans remains obscure, but 
our data indicates that it reduces HPV during acute isocapnic hypoxia in a pH or PCO2 
dependent manner. 
Finally, PVR increased in AZ+HCO3
- compared to control and AZ.  Such a response 
must be interpreted carefully.  Although pH and bicarbonate levels have been temporarily 
normalised, AZ is still present in the system and acting on carbonic anhydrase.  As such, PaO2 
and PaCO2, while not statistically different from control are still partially elevated and decreased 
respectively.  Perhaps a more important comparison is the relative hypercapnia with AZ+HCO3
- 
compared with AZ.  Since CO2 has pulmonary vasoconstrictive effects it may be possible that 
this has contributed to a greater PVR compared to AZ independent of the normalisation of 
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[HCO3
-] and pH.  Indeed, respiratory acidosis increases PVR significantly (Fullerton et al., 
1993), with our results suggesting relative hypercapnia as the primary mediator. 
Limitations 
The limitations of using microbubble passage as an index of blood flow through IPAVA has 
been described extensively (Elliott et al., 2011).  Given the size and composition of the bubbles, 
the only pathway for agitated contrast to appear in the left atrium/ventricle in participants lacking 
an intracardiac shunt is through IPAVA or pulmonary arteriovenous malformations.  It is 
unlikely that our participants had pulmonary arteriovenous malformations as resting arterial PO2 
and oxyhaemoglobin saturation were in the normal range.  In addition, no participants were 
identified as having left ventricle contrast during our screening at rest.  
The degree of HPV as indexed by PASP during hypoxia was smaller than expected.  
Although it is known to be a highly variable response, we employed similar techniques to 
Teppema et al. (2007) and found nearly a 50% smaller change in PASP in response to a similar 
isocapnic hypoxia protocol.  Several differences between the two studies may contribute to the 
differences between the studies.  Firstly, data were collected at slightly different altitudes; the 
study by Teppema et al. (2007) was performed at an elevation of 1100 m while the present study 
was conducted at lower altitudes (75 m (n = 3) and 344 m (n = 7)).  Consequently, their 
participants had lower resting SpO2, though we demonstrated greater desaturation following 
acute isocapnic hypoxia.  Chronic exposure to this mild altitude may blunt peripheral 
chemosensitivity (Weil et al., 1971), and this is suggested by the reduced resting ventilation seen 
in the participants tested at 1100 m.  The difference in altitude may have contributed to a blunted 
peripheral chemoreceptor responsiveness and increased HPV (Albert & Swenson, 2014).  
Secondly, our group of participants did not have intracardiac shunts whereas the status of the 
participants in the study by Teppema et al. (2007) is not known.  The presence of an intracardiac 
shunt could exaggerate arterial hypoxaemia leading to a greater degree of HPV (Levine et al., 
1991).  Since an intracardiac shunt like a PFO is present in approximately a third of the general 
population (Elliott et al., 2013; Marriott et al., 2013), our exclusion criteria may have favoured 
the recruitment of low HPV-responders.  Despite this, in the range of PASP measured in this 
study, we found no relationship between blood flow through IPAVA and PASP, Q̇c, or PVR.  In 
addition, across our three conditions we can also infer that blood flow through IPAVA is not 
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affected by the humoral manipulations of arterial pH and PCO2, at least over the range studied in 
this investigation.  
Finally, it must be acknowledged that AZ is a mild diuretic (Kassamali & Sica, 2011).  A 
non-significant increase in Hb (Table 1) supports such an action, which in turn may contribute to 
the lower PASP observed in the AZ condition.  While infusion of NaHCO3 did not exceed 220 
ml in any participants, Hb did decrease by nearly 1 g dl-1 indicating possible volume expansion.  
However, the Hb concentration with NaHCO3 was not different compared to control suggesting 
that pulmonary pressure may be slightly reduced at baseline with AZ as a result of its diuretic 
effect.  We recognize that acute volume loading increases pulmonary pressure.  However, a dose 
of less than 300 ml has minimal effect on pulmonary artery and capillary pressure (Doyle et al., 
1951) and our experimental trials did not exceed this value.  On the other hand, the effect of 
increasing volume does not speak to the PASP response to hypoxia.  In anesthetized and 
paralyzed dogs, Benumof and Wahrenbrock (1975) observed an inverse relationship between 
blood volume and hypoxic pulmonary vasoconstriction in dogs (r = 0.69; p<0.01).  From this 
association, they suggest that increased blood volume reduces the pulmonary vasocontstrictive 
response to hypoxia due to increased intravascular pressures.  Hence, the small change in fluid 
volume combined with the relative hypercapnia in our study (see Tables 1 & 2) could have 
contributed to the betwee-condition differences in pulmonary haemodynamics.  To address this 
potential influence, future studies require an experimental condition with an equimolar sodium 
challenge with saline.   Based on the conclusions of Benumof and Wahrenbrock (1975), the 
infusion of NaHCO3 may have blunted hypoxic pulmonary vasoconstriction in our study.  
Therefore, had we accounted for the volume loading during control and AZ, restoration of acid-
base status may have led to a complete, rather than partial, restoration of PASP and hypoxic 
pulmonary vasoconstriction.  The haemoglobin changes identified above would lead to a 2% 
increase in haematocrit.  Thus, a change in blood viscosity could contribute to the changes in 
pulmonary pressure.  However, we calculated PVR for a standardized haematocrit of 45% (Faoro 
et al., 2014).  By accounting for this 2% difference in haematocrit we would observe a PVR of 
1.38 and 1.40 in control and AZ.  Thus, the small differences in haemoglobin have little effect on 
PVR suggesting that the PASP measurements between the three comparisons are unlikely to be 
attributable to changes in blood viscosity. 
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Conclusion 
In conclusion, we found that manipulating pulmonary artery pressure during isocapnic hypoxia 
has no effect on the magnitude of blood flow through IPAVA.  Oral dosing of AZ was effective 
in reducing PASP not only at rest but also during exposure to isocapnic hypoxia.  For the first 
time, we have demonstrated that the reduction in PASP with AZ could be abolished by 
correction of bicarbonate, indicating that the effects of AZ on the pulmonary vasculature are 
related to pH or arterial/alveolar PCO2.  PASP did not influence blood flow through IPAVA, 
suggesting that the stimulus for their recruitment may be in response to acute hypoxia or 
pulmonary blood flow rather than pressure per se.  The relatively lower magnitudes of blood 
flow through IPAVA and increases in PASP we observed compared to previous studies may 
indicate that there is an additive effect of hypoxic stimuli and elevated pressure in promoting 
blood passage through IPAVA.  
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Tables. 
Table 1.  Resting haematological measurements made prior to each experimental condition (Control; AZ; 
AZ+HCO3-) and following AZ+HCO3-. 
 
 Control AZ AZ+HCO3
- Post AZ+HCO3
- 
n 10 10 10 7 
PaO2, mmHg 89.0 ± 3.9 98.0 ± 2.4 93.9 ± 3.8 92.8 ± 2.9 
PaCO2, mmHg 40.3 ± 1.1 35.8 ± 1.0
* 37.9 ± 0.8 36.7 ± 0.7 
pH 7.43 ± 0.01 7.34 ± 0.01‡ 7.43 ± 0.01 7.39 ± 0.01† 
[HCO3
-], mmol l-1 26.0 ± 0.6 18.9 ± 0.4‡ 24.7 ± 0.5 22.0 ± 0.6** 
[Hb], g dl-1 14.7 ± 0.3 15.4 ± 0.3 14.5 ± 0.3 15.1 ± 0.4 
Values are means ± SE.  *p<0.01 compared to control;  †p<0.01 compared to AZ and p<0.05 compared to 
AZ+HCO3- (n = 7); ‡p<0.001 compared to control and AZ+HCO3-.  **p<0.01 compared to Control, AZ, 
and AZ+HCO3-  (n = 7).  Definition of abreviations:  AZ = acetazolamide; PaO2 = arterial partial pressure 
of oxygen; PaCO2 = arterial partial pressure of carbon dioxide; [HCO3-] = concentration of bicarbonate; 
[Hb] = concentration of haemoglobin. 
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Table 2. Haemodynamic and cardiopulmonary response during control, AZ and AZ+HCO3
- during normoxia and hypoxia. 
  Control AZ AZ+HCO3
- Oxygen Level Condition Interaction 
PETO2, mmHg Normoxia 92.9 ± 1.7 101.3 ± 2.0** 99.2 ± 1.6* <0.001 <0.001 <0.001 
 Hypoxia 46. 7 ± 0.7 46.8 ± 0.4 46.7 ± 0.4    
PETCO2, mmHg Normoxia 39.7 ± 0.5 35.0 ± 0.7** 36.5 ± 0.4** <0.05 <0.001 0.200 
 Hypoxia 39.9 ± 0.5 35.8 ± 0.7 36.9 ± 0.4    
V̇E, l·min-1 Normoxia 11.9 ± 0.6 13.0 ± 0.6 12.7 ± 0.5 <0.05 0.971 0.341 
 Hypoxia 21.2 ± 3.9 19.5 ± 2.5 20.1 ± 1.9    
SpO2, % Normoxia 97.7 ± 0.3 97.7 ± 0.4 98.1 ± 0.3 <0.001 0.566 0.501 
 Hypoxia 80.4 ± 1.8 78.8 ± 1.1 79.5 ± 1.3    
HR, beats·min-1 Normoxia 57 ± 2 55 ± 3 56 ± 3 <0.001 0.0596 0.609 
 Hypoxia 68 ± 3 63 ± 4 67 ± 4    
SV, ml Normoxia 77.9 ± 3.7 77.1 ± 5.0 76.6 ± 3.9 0.962 0.493 0.660 
 Hypoxia 82.3 ± 4.2 74.7 ± 5.5 74.2 ± 4.2    
Q̇c, l·min-1 Normoxia 4.0 ± 0.2 3.9 ± 0.3 4.2 ± 0.2 <0.001 0.700 0.565 
 Hypoxia 5.2 ± 0.4 4.8 ± 0.4 4.8 ± 0.3    
MAP, mmHg Normoxia 86 ± 2 84 ± 2 86 ± 2 <0.05 0.796 0.644 
 Hypoxia 90 ± 3 91 ± 5 93 ± 4    
PVR, wu Normoxia 1.35 ± 0.04 1.43 ± 0.05 1.62 ± 0.08† 0.065 <0.01 0.449 
 Hypoxia 1.53 ± 0.06 1.48 ± 0.04 1.66 ± 0.06    
Values are means ± SE.  *p<0.05 compared to control; **p<0.001 compared to control; †p<0.01 compared to AZ and control.  The 
oxygen level, condition and interaction columns display the p-value for the effect of condition (control, AZ, AZ+HCO3
-) and the effect 
of oxygen level (normoxia, hypoxia).  Definition of abbreviations:  AZ = acetazolamide; HR = heart rate; MAP = mean arterial 
pressure; PETO2 = end-tidal partial pressure of oxygen; PETCO2 = end-tidal partial pressure of carbon dioxide; PVR = pulmonary 
vascular resistance; SV = stroke volume; Q̇c = cardiac output; V̇E = minute ventilation 
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Figures and legends 
Figure 1. End-tidal gases (PETO2 and PETCO2) and minute ventilation (V̇E) at baseline and 
throughout 20 min of isocapnic hypoxia for all participants (n = 10).  Data points are 15 s mean ± 
SE.  Definition of abbreviations: PETO2: end-tidal partial pressure of oxygen; PETCO2: end-tidal 
partial pressure of carbon dioxide; Control, isocapnic hypoxia intervention; AZ, acetazolamide 
intervention, AZ+HCO3
-: bicarbonate correction intervention. 
Figure 2. Individual and group mean pulmonary artery systolic pressure (PASP) during 
normoxia and isocapnic hypoxia during (A) control, (B) acetazolamide (AZ) and (C) AZ and 
intravenous NaHCO3 (AZ+HCO3
-).  A significant main effect of hypoxia (p<0.001) and 
condition (p<0.01) were found. For the condition interaction, post hoc analysis revealed a 
difference between the control and AZ conditions.  Means ± SE of each condition are provided 
above the x-axis. * = p<0.001, hypoxia compared to normoxia; † = p<0.001AZ compared to 
control. Control, isocapnic hypoxia intervention; AZ, acetazolamide intervention, AZ+HCO3
-: 
bicarbonate correction intervention; PASP, pulmonary artery systolic pressure. 
Figure 3. Bubble scores during the isocapnic hypoxia trial in each condition (n = 10). Each data 
point represents a participant with their corresponding bubble score on the y-axis. There were no 
significant differences between the conditions (p>0.05). Control, isocapnic hypoxia intervention; 
AZ, acetazolamide intervention; AZ+HCO3
-, bicarbonate correction intervention. 
Figure 4. Relationship between bubble score and (A), PASP (mmHg), (B), Q̇c (l·min-1) and (C), 
PVR (wu) during hypoxia in each condition. Multiple linear regression revealed no significant 
linear relationships (R2 = 0.008, 0.08 and 0.0006 for (A), (B), and (C) respectively; all p>0.05). 
Control, isocapnic hypoxia intervention; AZ, acetazolamide intervention, AZ+HCO3
-: 
bicarbonate correction intervention; PASP, pulmonary artery systolic pressure; PVR, pulmonary 
vascular resistance; Q̇c, cardiac output. 
Figure 5. Effect of isocapnic versus poikilocapnic hypoxia on the relationship between cardiac 
output (Q̇c) and bubble score.  Bubble scores and Q̇c obtained during the last minute of exposure 
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to 20 minutes of isocapnic hypoxia from the current study (n = 10) and poikilocapnic hypoxia 
from participants in the study by Laurie et al. (2010) (n = 12) breathing 12% O2 for 30 minutes. 
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